Sep 12, 2019
NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split
Aug 26, 2019
NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND
Aug 05, 2019
NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials
Jun 10, 2019
NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors
May 20, 2019
NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide(TM) Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials
Apr 16, 2019
NanoViricides Submits Pre-IND Briefing Documents to the US FDA
Apr 09, 2019
NanoViricides Provides Update on Pre-IND Meeting with the US FDA, GLP Safety/Toxicology Studies to Begin Soon, Multiple Kg Scale Drug Production Accomplished at Its Own Facility
Mar 26, 2019
NanoViricides has Requested a Pre-IND Meeting with the US FDA
Mar 12, 2019
NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND
Mar 05, 2019
NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study
Feb 27, 2019
NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering
Feb 26, 2019
NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development
Feb 19, 2019
NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials
Feb 11, 2019
NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2:30pm
Feb 04, 2019
NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials
Jan 02, 2019
NanoViricides, Inc. CEO Dr. Taraporewala To Present At The Biotech Showcase(TM) Investment Conference In San Francisco on January 7, 2019
Nov 26, 2018
NanoViricides Files Quarterly Report for Period Ending September 30, 2018
Oct 29, 2018
NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors
Oct 22, 2018
NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders
Oct 15, 2018
NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program